Pangaea Oncology, S.A.
MCE PANG.MC
Pangaea Oncology, S.A. Price to Sales Ratio (P/S) on January 13, 2025: 6.96
-
Pangaea Oncology, S.A. 52-week high Price to Sales Ratio (P/S) is 7.78 on October 29, 2024, which is 11.77% above the current Price to Sales Ratio (P/S).
-
Pangaea Oncology, S.A. 52-week low Price to Sales Ratio (P/S) is 6.71 on December 23, 2024, which is -3.58% below the current Price to Sales Ratio (P/S).
-
Pangaea Oncology, S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 7.22.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Mr. Javier Rivela-Rodriguez C.F.A., M.B.A. |
| IPO Date | Sept. 19, 2017 |
| Location | Spain |
| Headquarters | Sabino Arana, 5-19 |
| Employees | 149 |
| Sector | Health Care |
| Industries | |
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation, validation against commercially available platforms, and Ad-hoc R+D for diagnostics companies. It also provides biomarker discovery to identify novel targets for targeted therapies in pre-clinical development. Pangaea Oncology, S.A. was founded in 2006 and is based in Barcelona, Spain.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email